Compare Biogen Inc (BIIB) vs Coinbase Global, Inc. (COIN) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

COIN trades at $148.4, down 0.19% with a bearish technical signal. Recent earnings misses and a net loss in Q2 2026 highlight challenges despite revenue growth. The stock faces pressure from a sluggish crypto market, but maintains strong cash flow and a 55% analyst buy rating with a $207.20 price target.

Outlook remains mixed: strong fundamentals like positive EBITDA and cash flow support long-term potential, but near-term risks from earnings volatility and market sentiment weigh on performance. Investors should balance growth prospects against sector headwinds.